Galcanezumab

Pain / Migraine Prevention

Also known as: Emgality

Anti-CGRP AntibodiesResearch phase: Extensive human data (post-marketing)Regulatory: FDA-approved (2018) for migraine prevention. FDA-approved (2019) for episodic cluster headache — first ever approved cluster headache preventive. Emgality (Eli Lilly). 120mg SC monthly.

Mechanism

An antibody that neutralizes CGRP for migraine prevention — and notably the first-ever approved preventive treatment for episodic cluster headache ("suicide headache"). Given as a monthly self-injection with a loading dose on the first month. Reduces migraine frequency and has brought real relief to cluster headache sufferers who previously had almost no preventive options.

Technical detail

Humanized IgG4 monoclonal antibody binding CGRP ligand with high affinity (KD ~31 pM). IgG4 subclass selected for minimal Fc effector function and reduced complement activation. Binds CGRP at a distinct epitope vs. fremanezumab, primarily targeting the C-terminal region critical for receptor binding. Phase 3 EVOLVE-1/2 (episodic migraine): 120mg monthly reduced migraine days by 4.7 (vs. 2.8 placebo). Phase 3 REGAIN (chronic migraine): 4.8 fewer migraine days vs. 2.7 placebo. Phase 3 cluster headache trial: reduced weekly attacks by 8.7 (vs. 5.2 placebo) in episodic cluster — first positive preventive trial in cluster headache history. Dosing: 240mg loading dose (2 x 120mg), then 120mg monthly. For cluster headache: 300mg monthly (3 x 100mg injections). Half-life ~27 days. Injection site reactions (18%) most common AE. No hepatotoxicity.

Effects

NERVOUS SYSTEM (MIGRAINE AND CLUSTER HEADACHE): Galcanezumab (Emgality) is a humanized monoclonal antibody that binds and neutralizes CGRP ligand — similar to fremanezumab but with a unique distinction: galcanezumab is the first and only FDA-approved preventive treatment for episodic cluster headache, one of the most severe pain conditions known [RCT — Goadsby et al., 2019, NEJM]. MIGRAINE PREVENTION: EVOLVE-1 and EVOLVE-2 trials in episodic migraine — galcanezumab 120mg (after 240mg loading dose) and 240mg monthly reduced monthly migraine days by -4.7 and -4.6 (vs. -2.8 placebo) in EVOLVE-1 [RCT — Stauffer et al., 2018]. 50% responder rate: 62% at 120mg, 61% at 240mg (vs. 39% placebo) — notably higher absolute responder rates than reported in erenumab and fremanezumab trials, though cross-trial comparisons must be made cautiously [RCT]. REGAIN trial in chronic migraine: -4.8 days (120mg) and -4.6 days (240mg) vs. -2.7 placebo [RCT]. CLUSTER HEADACHE: The landmark CGAL study (Goadsby et al., 2019, NEJM) randomized 106 patients with episodic cluster headache to galcanezumab 300mg SC monthly vs. placebo. Galcanezumab reduced weekly cluster headache attacks by -3.5 (vs. -0.2 placebo) across weeks 1-3 — a dramatic and clinically meaningful effect [RCT]. 71% of galcanezumab patients achieved ≥50% reduction in weekly attack frequency (vs. 30% placebo) [RCT]. This was the first preventive therapy ever approved for episodic cluster headache — patients previously had no FDA-approved preventive option (verapamil is used off-label). Note: the chronic cluster headache trial was NEGATIVE — galcanezumab did not show benefit in chronic cluster headache [Phase 3]. LOADING DOSE: Galcanezumab uses a 240mg loading dose (two 120mg injections at initiation), followed by 120mg monthly. This provides rapid initial CGRP neutralization and may accelerate onset of benefit [pharmacokinetic rationale]. CARDIOVASCULAR: No significant CV signals in trials or post-marketing [RCT, registry]. SIDE EFFECTS: Injection site reactions (~18%), injection site erythema, pruritus. Constipation less prominent than erenumab. Vertigo reported rarely [RCT, post-marketing].

Practitioner Guide

ADMINISTRATION: Subcutaneous injection, monthly. Prefilled pen (120mg) or prefilled syringe (100mg/mL and 150mg/mL). MIGRAINE DOSING: Loading dose: 240mg SC (two 120mg injections) at initiation. Maintenance: 120mg SC monthly. The loading dose is a differentiating feature — provides rapid CGRP neutralization and may result in benefit within the first week. Inject in abdomen, thigh, upper arm, or buttocks. CLUSTER HEADACHE DOSING: 300mg SC monthly (three 100mg injections). No loading dose specified in the cluster headache label. Start at the beginning of a cluster period. Duration of treatment: continue through the cluster period and reassess at each cycle. Some practitioners continue year-round in patients with frequent or unpredictable cluster periods. THE CLUSTER HEADACHE NICHE: This is galcanezumab's unique clinical position. Episodic cluster headache affects approximately 0.1% of the population and is described as the worst pain known to medicine ('suicide headache'). Prior to galcanezumab, the only preventive options were off-label verapamil (requires ECG monitoring, limited efficacy), lithium (narrow therapeutic window, toxicity), and short courses of corticosteroids (bridging only). Galcanezumab at 300mg monthly provides a well-tolerated, effective preventive with a clear treatment protocol. IMPORTANT: Only episodic cluster headache responded — chronic cluster headache (continuous without remission periods) did NOT respond in the Phase 3 trial. This distinction is clinically critical. LOADING DOSE ADVANTAGE: The 240mg loading dose is unique among CGRP antibodies. For patients in acute need of rapid migraine control (e.g., status migrainosus, rapid escalation), the loading dose may provide faster benefit than erenumab or fremanezumab (which have no loading dose). SWITCHING WITHIN CLASS: If a patient fails other CGRP antibodies, galcanezumab is reasonable to try — all three ligand-targeting antibodies bind different CGRP epitopes, and cross-response is not guaranteed. If erenumab (receptor-targeted) fails, switching to ligand-targeting makes mechanistic sense. COST AND ACCESS: Approximately $600-700/month for migraine dosing, higher for cluster headache dosing (300mg). Prior authorization required. Lilly patient assistance available. STORAGE: Refrigerate (2-8°C). Can store at room temperature (up to 30°C) for up to 7 days. Protect from light.

Evidence

Research Summary

TIER 1: EVOLVE-1 (Stauffer et al., 2018) and EVOLVE-2 (Skljarevski et al., 2018): Phase 3 episodic migraine — significant reduction in monthly migraine days with both 120mg and 240mg galcanezumab. REGAIN (Detke et al., 2018): Phase 3 chronic migraine — significant efficacy. CGAL (Goadsby et al., 2019 — NEJM): landmark Phase 3 in episodic cluster headache — first positive preventive trial in cluster headache history. 71% ≥50% responder rate (vs. 30% placebo). Chronic cluster headache trial: NEGATIVE — no significant benefit. FDA approved September 2018 (migraine), June 2019 (episodic cluster headache). Open-label extensions demonstrating sustained efficacy over 12+ months. TIER 2: Systematic reviews and meta-analyses of CGRP antibodies. Reviews comparing loading dose strategies across the class. Analysis of galcanezumab's unique cluster headache indication. Post-marketing safety reviews. Network meta-analyses suggesting galcanezumab may have slightly higher absolute response rates in episodic migraine (with caveats about cross-trial comparison). Reviews of cluster headache pathophysiology and the role of CGRP. TIER 3: Headache center real-world data on galcanezumab in migraine and cluster headache. Case reports of galcanezumab in other trigeminal autonomic cephalalgias (SUNCT, paroxysmal hemicrania — anecdotal). Patient-reported outcomes from cluster headache specialty clinics. Practitioner protocols for transitioning cluster headache patients to galcanezumab. KEY FINDINGS: Galcanezumab is differentiated from other CGRP antibodies by two features: the loading dose (rapid onset) and the episodic cluster headache indication (unique in the class and historic — first approved preventive for this devastating condition). Migraine efficacy is consistent with the CGRP class. The failure in chronic cluster headache is important — it may reflect different pathophysiology between episodic and chronic forms. GAPS: Why chronic cluster headache did not respond (different CGRP biology?). Head-to-head vs. other CGRP antibodies. Optimal duration in cluster headache. Predictors of cluster headache response. Long-term safety in cluster headache patients receiving 300mg doses. ACTIVE TRIALS: Galcanezumab in other headache disorders. Long-term extension studies. Comparative effectiveness in migraine. Investigations into chronic cluster headache non-response.

Build a personalized protocol with Galcanezumab →